Cardiff Oncology Inc is a clinical-stage oncology therapeutics company, developing onvansertib, a first-in-class, 3rd generation, oral, and highly-selectivePolo-like Kinase 1 (PLK1) inhibitor to treat patients with leukemia, lymphoma, and solid tumor cancers. The company is making advancements in its clinical development program, with three ongoingclinical trials: a Phase 1b/2 trial in Acute Myeloid Leukemia (AML); aPhase 2 trial in metastatic Castration-Resistant Prostate Cancer (mCRPC)and a Phase 1b/2 trial in metastatic Colorectal Cancer (mCRC). The firm's treatment includes KRAS-mutated metastatic colorectal cancer (mCRC), metastatic castrate-resistant prostate cancer (mCRPC), and acute myeloid leukemia (AML).
DarkPulse Inc is a technology-security company. It offers a full suite of engineering, installation, and security management solutions to industry and government. It provides a comprehensive data stream of critical metrics for assessing the health and security of their infrastructure. Its technology can determine wall deformation, corrosion, pipe wall thickness, pressure, strain, & temperature from sensor data collected in Real-Time. A DarkPulse system offers multiple power sources for continuous monitoring including solar and battery which allows for off-grid installations. Its products have applications in the following sectors: Structural Monitoring, Temperature Sensing, Security & Defense, Consulting Services, and others. https://www.darkpulse.com/